Ferroptosis-centered Drug Response Information
General Information of the Drug (ID: ferrodrug0248)
| Name |
Ruscogenin
|
||||
|---|---|---|---|---|---|
| Synonyms |
Ruscogenin; 472-11-7; UNII-BXI92R2VUJ; BXI92R2VUJ; CHEBI:8913; Spirost-5-ene-1,3-diol, (1b,3b,25R)-; (1beta,3beta,25R)-Spirost-5-ene-1,3-diol; EINECS 207-447-2; (25R)-spirost-5-en-1beta,3beta-diol; (25R)-Spirost-5-ene-1beta,3beta-diol; Spirost-5-ene-1,3-diol, (1.beta.,3.beta.,25R)-; Ruscogenins; Ruscorectal (TN); RUSCOGENIN [INCI]; RUSCOGENIN [MART.]; RUSCOGENIN [WHO-DD]; SCHEMBL147884; CHEMBL1169820; Ruscogenin, >=98% (HPLC); DTXSID401019319; HY-N0496; LMST01080038; MFCD00210550; CCG-269015; AC-34398; CS-0009017; S9183; C08909; D08498; Q-201689; (25R)-SPIROST-5-ENE-1.BETA.,3.BETA.-DIOL; Q27108184; SPIROST-5-ENE-1.BETA.,3.BETA.-DIOL, (25R)-; Z2037319104; (1S,2S,4S,5'R,6R,7S,8R,9S,12S,13R,14R,16R)-5',7,9,13-tetramethylspiro[5-oxapentacyclo[10.8.0.02,9.04,8.013,18]icos-18-ene-6,2'-oxane]-14,16-diol
Click to Show/Hide
|
||||
| Structure |
 |
||||
| Formula |
C27H42O4
|
||||
| IUPAC Name |
(1S,2S,4S,5'R,6R,7S,8R,9S,12S,13R,14R,16R)-5',7,9,13-tetramethylspiro[5-oxapentacyclo[10.8.0.02,9.04,8.013,18]icos-18-ene-6,2'-oxane]-14,16-diol
|
||||
| Canonical SMILES |
CC1CCC2(C(C3C(O2)CC4C3(CCC5C4CC=C6C5(C(CC(C6)O)O)C)C)C)OC1
|
||||
| InChI |
InChI=1S/C27H42O4/c1-15-7-10-27(30-14-15)16(2)24-22(31-27)13-21-19-6-5-17-11-18(28)12-23(29)26(17,4)20(19)8-9-25(21,24)3/h5,15-16,18-24,28-29H,6-14H2,1-4H3/t15-,16+,18-,19-,20+,21+,22+,23-,24+,25+,26+,27-/m1/s1
|
||||
| InChIKey |
QMQIQBOGXYYATH-IDABPMKMSA-N
|
||||
| PubChem CID | |||||
Full List of Ferroptosis Target Related to This Drug
Unspecific Target
| In total 1 item(s) under this Target | |||||
| Experiment 1 Reporting the Ferroptosis-centered Drug Act on This Target | [1] | ||||
| Responsed Disease | Pancreatic cancer | ICD-11: 2C10 | |||
| Pathway Response | Ferroptosis | hsa04216 | |||
| Cell Process | Cell ferroptosis | ||||
| Cell proliferation | |||||
| In Vitro Model | BxPC-3 cells | Pancreatic ductal adenocarcinoma | Homo sapiens | CVCL_0186 | |
| SW1990 cells | Pancreatic adenocarcinoma | Homo sapiens | CVCL_1723 | ||
| PANC-1 cells | Pancreatic ductal adenocarcinoma | Homo sapiens | CVCL_0480 | ||
| AsPC-1 cells | Pancreatic ductal adenocarcinoma | Homo sapiens | CVCL_0152 | ||
| HPDE6-C7 cells | Normal | Homo sapiens | CVCL_0P38 | ||
| In Vivo Model |
A total of 15 six-week-old female BALB/c nude mice (25.2-25.9 g) were purchased from SLAC Animal Laboratories. Approximately 1 x 106 BxPC-3 cells were subcutaneously implanted into the right flank of the nude mice. The tumors were allowed to grow to approximately 120 mm3 in size and a total of 15 tumor-bearing mice were divided randomly into 3 groups (n = 5 per group). Group 1 was injected with 0.1 ml PBS as control; group 2 and 3 received 5 and 10 mg/kg ruscogenin, respectively twice per week.
Click to Show/Hide
|
||||
| Response regulation | Ruscogenin exerts anticancer function in pancreatic cancer cells by inducing ferroptosis. Ruscogenin improved ROS generation and increased intracellular iron by regulating transferrin and ferroportin. | ||||